Work

O01: Efficacy and safety outcomes of JNT-517, a first-in-class SLC6A19 inhibitor, in adults with phenylketonuria: A randomized study

Year: 2025

Type: article

Source: Genetics in Medicine Open

DOI: 10.1016/j.gimo.2025.101964

Authors: Cary Harding, Nicola Longo, Andreu Viader, Toby Vaughn, Fernanda Leal-Pardinas, Elaina Jurecki, Markey McNutt, Ania Muntau, Rani Singh, Joel Barrish, George Vratsanos, Haoling Weng, John Throup

Institutions: Oregon Health & Science University, University of California, Los Angeles, Jnana Therapeutics (United States), The University of Texas Southwestern Medical Center, University Medical Center Hamburg-Eppendorf, Emory University

Language: English

Topic: Metabolism and Genetic Disorders

Subfield: Clinical Biochemistry

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,200

OpenAlex ID: W4408532667

FWCI: 1.293

Cites:

Cited by: 2

Related to: 10